Apadenoson
| Code | Size | Price |
|---|
| TAR-T26641-5mg | 5mg | £1,251.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26641-50mg | 50mg | £2,464.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26641-100mg | 100mg | £3,283.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Apadenoson is an adenosine A2A agonist. ATL-146e attenuates experimental posthemorrhagic vasospasm. ATL-146e reduces systemic tumor necrosing factor-alpha and spinal cord capillary platelet-endothelial cell adhesion molecule-1 expression after spinal cord ischemia. ATL-146e prevents concanavalin A-induced acute liver injury in mice. ATL-146e, reduces paralysis and apoptosis during rabbit spinal cord reperfusion.
CAS:
250386-15-3
Formula:
C23H30N6O6
Molecular Weight:
486.529
Purity:
0.98
SMILES:
CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(nc12)C#CC[C@H]1CC[C@@H](CC1)C(=O)OC
References
1. Patel RA, Glover DK, Broisat A, Kabul HK, Ruiz M, Goodman NC, Kramer CM, Meerdink DJ, Linden J, Beller GA. Reduction in myocardial infarct size at 48 hours after brief intravenous infusion of ATL-146e, a highly selective adenosine A2A receptor agonist. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H637-42. doi: 10.1152/ajpheart.00705.2008. Epub 2009 Jun 5. PubMed PMID: 19502555; PubMed Central PMCID: PMC2724215.
2. Chang CZ, Dumont AS, Simsek S, Titus BJ, Kwan AL, Kassell NF, Solenski NJ. The adenosine 2A receptor agonist ATL-146e attenuates experimental posthemorrhagic vasospasm. Neurosurgery. 2007 Jun;60(6):1110-7; discussion 1117-8. PubMed PMID: 17538386.
3. Reece TB, Kron IL, Okonkwo DO, Laurent JJ, Tache-Leon C, Maxey TS, Ellman PI, Linden J, Tribble CG, Kern JA. Functional and cytoarchitectural spinal cord protection by ATL-146e after ischemia/reperfusion is mediated by adenosine receptor agonism. J Vasc Surg. 2006 Aug;44(2):392-7. PubMed PMID: 16890874.
4. Odashima M, Otaka M, Jin M, Horikawa Y, Matsuhashi T, Ohba R, Linden J, Watanabe S. A selective adenosine A2A receptor agonist, ATL-146e, prevents concanavalin A-induced acute liver injury in mice. Biochem Biophys Res Commun. 2006 Sep 8;347(4):949-54. Epub 2006 Jul 21. PubMed PMID: 16859640.